Biosimilar BI 695501 and Adalimumab Reference Product (RP) Have Similar Efficacy and Safety in Patients (pts) with Moderately-to-Severely Active Rheumatoid Arthritis (RA): Long-Term Results from a Phase IIIb Extension Study (VOLTAIRE®-RAext)

被引：0
|
作者：
Cohen, Stanley [1 ]
Czeloth, Niklas [2 ]
Lees, Eric [3 ]
Klimiuk, Piotr A. [4 ,5 ]
Peter, Nuala [6 ]
Jayadeva, Girish [2 ]
机构：
[1] Metroplex Clin Res Ctr, Dallas, TX USA
[2] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
[3] Inland Rheumatol, Upland, CA USA
[4] Med Univ Bialystok, Bialystok, Poland
[5] Gabinet Internistyczno Reumatol, Bialystok, Poland
[6] Boehringer Ingelheim GmbH & Co KG, Biberach, Germany
来源：
ARTHRITIS & RHEUMATOLOGY | 2018年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2522
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Similar Efficacy, PK, Safety, and Immunogenicity of Tocilizumab Biosimilar (CT-P47) and Reference Tocilizumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: Week 52 Results from the Phase III Single Transition Study
    Burmester, Gerd
    Trefler, Jakub
    Racewicz, Artur
    Jaworski, Janusz
    Zielinska, Agnieszka
    Krogulec, Marek
    Jeka, Slawomir
    Wojciechowski, Rafal
    Kolossa, Katarzyna
    Dudek, Anna
    Krajewska-Wlodarczyk, Magdalena
    Hrycaj, Pawel
    Klimiuk, Piotr Adrian
    Kim, SungHyun
    Suh, JeeHye
    Yang, Goeun
    Kim, Yunah
    Jung, YooBin
    Hong, Jiwoo
    Smolen, Josef
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 1017 - 1019
  • [42] IMPACT OF ANTI-DRUG ANTIBODIES ON EFFICACY AND SAFETY UP TO WEEK 24 FROM A PHASE III STUDY COMPARING SB5 (AN ADALIMUMAB BIOSIMILAR) WITH ADALIMUMAB REFERENCE PRODUCT IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPY
    Genovese, M. C.
    Weinblatt, M.
    Keystone, E.
    Baranauskaite, A.
    Cheong, S. Y.
    Ghil, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 234 - 234
  • [43] LONG-TERM SAFETY AND EFFICACY OF SB4 (ETANERCEPT BIOSIMILAR) IN PATIENTS WITH RHEUMATOID ARTHRITIS: COMPARISON BETWEEN CONTINUING SB4 AND SWITCHING FROM ETANERCEPT REFERENCE PRODUCT TO SB4
    Emery, P.
    Vencovsky, J.
    Sylwestrzak, A.
    Leszczynski, P.
    Porawska, W.
    Stasiuk, B.
    Hilt, J.
    Mosterova, Z.
    Cheong, S. Y.
    Ghil, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 236 - 236
  • [44] Efficacy and Safety of Upadacitinib After 3 Years of Treatment in Patients With Moderately to Severely Active Ulcerative Colitis: Interim Long-Term Data From the Phase 3 Open-Label Extension Study (U-ACTIVATE)
    Panaccione, Remo
    Higgins, Peter
    Nakase, Hiroshi
    Glover, Sarah C.
    Danese, Silvio
    Colombel, Jean-Frederic
    Eccleston, Jason
    Kujawski, Michelle
    Remple, Valencia
    Yao, Xuan
    Suravaram, Smitha
    Schreiber, Stefan
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10): : S1061 - S1062
  • [45] Efficacy and safety of upadacitinib after 4 years of treatment in patients with moderately to severely active ulcerative colitis: interim long-term data from the phase 3 open-label extension study (U-ACTIVATE)
    Panaccione, R.
    Lichtenstein, G.
    Colombel, J. F.
    Nakase, H.
    Yao, X.
    Klaff, J.
    Kujawski, M.
    Rizzo, L.
    Suravaram, S.
    Vermeire, S.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i80 - i82
  • [46] FIVE-YEAR SAFETY AND EFFICACY OF SUBCUTANEOUS ABATACEPT IN PATIENTS WITH MODERATE TO SEVERELY ACTIVE RA AND AN INADEQUATE RESPONSE TO MTX: LONG-TERM EXTENSION OF THE PHASE III, DOUBLE-BLIND, RANDOMIZED ACQUIRE STUDY
    Genovese, M. C.
    Tena, C. Pacheco
    Covarrubias, A.
    Leon, G.
    Mysler, E.
    Keiserman, M.
    Valente, R.
    Nash, P.
    Simon-Campos, J. A.
    Box, J.
    Legerton, C. W., III
    Nasonov, E.
    Durez, P.
    Elegbe, A.
    Wong, R.
    Li, X.
    Banerjee, S.
    Alten, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 515 - 515
  • [47] 5 Year Safety, Efficacy, and Radiographic Data in Patients with Active Psoriatic Arthritis Treated with Golimumab: Results From the Long-Term Extension of a Randomized, Placebo-Controlled Study
    Kavanaugh, Arthur
    van der Heijde, Desiree
    McInnes, Iain B.
    Mease, Philip
    Krueger, Gerald G.
    Gladman, Dafna
    Zhou, Yiying
    Lu, J. D.
    Xu, Zhenhua
    Noonan, Lenore
    Beutler, Anna
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S938 - S939
  • [48] Long-term efficacy and safety of adalimumab (D2E7) monotherapy in patients with DMARD-refractory rheumatoid arthritis - Results from a 2-year study.
    Burmester, GR
    van de Porte, LBA
    Rau, R
    Breedveld, FC
    Kalden, JR
    Malaise, M
    Schattenkircher, M
    Emery, P
    Beck, K
    Dressler, R
    Kupper, H
    ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S537 - S537
  • [49] Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study (vol 8, e002012, 2022)
    Fleischmann, R.
    Mysler, E.
    Bessette, L.
    RMD OPEN, 2023, 9 (02):
  • [50] Janus kinase inhibitor baricitinib for rheumatoid arthritis: Randomized, double-blind, placebo- and active-controlled, phase 3 study evaluating the efficacy and safety of baricitinib in patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to methotrexate therapy (RA-BEAM)
    Alten R.
    Nitschmann S.
    Der Internist, 2017, 58 (12): : 1341 - 1344
12345